ImageneBio Stock Performance
| IMA Stock | 5.84 -0.18 -2.99% |
The company owns a Beta (Systematic Risk) of 0.71, which signifies possible diversification benefits within a given portfolio. ImageneBio moves in the same direction as the market but with less intensity, offering a degree of cushion during selloffs. At this point, ImageneBio has a negative expected return of -0.0296%. Please make sure to confirm ImageneBio's potential upside, accumulation distribution, and the relationship between the treynor ratio and day median price, to decide if ImageneBio's performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weak
Weak | Strong |
For the recent 90-day horizon, ImageneBio failed to convert risk into positive risk-adjusted performance. The business is commonly classified in the Healthcare sector and the Biotechnology industry. Despite somewhat strong primary indicators, ImageneBio is not utilizing all of its potential. The current price disturbance may contribute to short-term losses for investors. Learn More
Actual Historical Performance (%)
One Day Return -2.90 | Five Day Return 0.17 | Year To Date Return -10.95 | Ten Year Return -98.43 | All Time Return -98.43 |
Last Split Factor 1:12 | Last Split Date 2025-07-28 |
1 | Acquisition by Slattery Joseph P of 16000 shares of Imagene Bio at 5.99 subject to Rule 16 b-3 | 12/24/2025 |
2 | Top Imagene Bio Insider Makes Bold New Move on Company Stock - Tip Ranks | 12/29/2025 |
3 | Acquisition by Erin Butler of 22500 shares of Imagene Bio at 7.11 subject to Rule 16 b-3 | 12/30/2025 |
4 | Joseph Slattery Spends US 96 k On Imagene Bio Stock | 12/31/2025 |
5 | Breaking News IMA Senior Fellow Dr. Kimberly Biss Appointed to Advisory Committee on Immunization Practices | 01/13/2026 |
6 | CPA Crossings Partners with IMA to Expand Continuing Education Opportunities for Accounting and Finance Professionals | 01/20/2026 |
7 | Imagene Bio Debuts on Nasdaq Following Merger Completion - AD HOC NEWS | 02/06/2026 |
8 | New IMA Study Challenges Measles Narrative Data Shows Robust Options for Acute Management | 02/12/2026 |
9 | Insider Trading | 02/13/2026 |
10 | Imagene Bio announces immediate resignation of board director - Tip Ranks | 02/17/2026 |
11 | Acquisition by Germa Caroline of 579100 shares of Imagene Bio at 1.47 subject to Rule 16 b-3 | 02/20/2026 |
12 | Imagene Bio to Participate in Leerink Global Healthcare Conference | 02/26/2026 |
13 | Imagene Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update | 03/10/2026 |
14 | Imagene Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 03/17/2026 |
| Begin Period Cash Flow | 12.1 M | |
| Total Cashflows From Investing Activities | -5.8 M |
ImageneBio | Build portfolio with ImageneBio Stock |
Relative Risk vs. Return Landscape
If you had invested $ 619.00 in ImageneBio on December 18, 2025 and sold it today you would have lost $ 35.50 from holding ImageneBio or given up 5.74% of portfolio value over 90 days. ImageneBio is generating negative expected returns assuming volatility of 3.7469% on return distribution over 90 days investment horizon. In other words, 33% of stocks are less volatile than ImageneBio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
Prices of stocks like ImageneBio Stock tend to oscillate around a central value over time, a phenomenon known as mean reversion. Although this tendency is a useful forecasting input, some instruments remain persistently underpriced or overpriced before the market corrects the discrepancy.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 5.84 | 90 days | 5.84 | over 95.29 |
Under a normal probability framework, the likelihood of ImageneBio moving above the current price in 90 days from now is over 95.29 (The distribution above models the probability of ImageneBio Stock reaching different price points within 90 days).
ImageneBio Price Density |
| Price |
Predictive Modules for ImageneBio
The challenge of forecasting ImageneBio mirrors the broader difficulty of predicting stock market movements. No single technique offers reliable accuracy, but investors who apply multiple methods and compare the results are better positioned to identify potential outcomes and manage risk effectively.While mean reversion in ImageneBio is a statistically observable tendency, it operates on uncertain timelines. Positions sized too aggressively against the trend can suffer sustained losses before reversion occurs.
Primary Risk Indicators
The stock market has been marked by significant volatility in the last 10-20 years, and ImageneBio has not been spared. Both sharp declines and strong rallies have tested investor discipline. A hedging strategy built around ImageneBio's risk indicators can help those holding ImageneBio manage downside risk more effectively.α | Alpha over Dow Jones | -0.0173 | |
β | Beta against Dow Jones | 0.71 | |
σ | Overall volatility | 0.46 | |
Ir | Information ratio | -0.0015 |
Investor Alerts and Insights
Investors who use alerts for ImageneBio can respond more quickly to important stock events. Notifications for ImageneBio highlight significant technical and fundamental shifts that may create new opportunities or signal emerging risks.| ImageneBio generated a negative expected return over the last 90 days | |
| ImageneBio has high historical volatility and very poor performance | |
| ImageneBio has high likelihood to experience some financial distress in the next 2 years | |
| ImageneBio was previously known as Ikena Oncology and was traded on NASDAQ Exchange under the symbol IKNA. | |
| The company reported last year's revenue of 800 K. Reported Net Loss for the year was -52.4 M with profit before taxes, overhead, and interest of 4.3 M. | |
| ImageneBio generates negative cash flow from operations | |
| ImageneBio has a frail financial position based on the latest SEC disclosures | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Imagene Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Price Density Drivers
ImageneBio price dynamics are shaped by the balance between buyer and seller activity. When short interest rises or long traders begin reducing positions, volatility tends to increase. Key market indicators are shown below.
| Common Stock Shares Outstanding | 4.9 M | |
| Cash And Short Term Investments | 75.8 M |
ImageneBio Fundamentals Growth
Investor sentiment toward ImageneBio Stock is largely driven by ImageneBio's fundamental metrics. Revenue growth rates, earnings per share trends, profit margin changes, and leverage ratios are among the most impactful factors determining ImageneBio Stock market behavior.
| Operating Margin | -5.01 % | |||
| Current Valuation | -69.81 M | |||
| Shares Outstanding | 11.18 M | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 86.66 X | |||
| Revenue | 800 K | |||
| Gross Profit | 4.3 M | |||
| EBITDA | -47.42 M | |||
| Net Income | -52.4 M | |||
| Total Debt | 9.99 M | |||
| Book Value Per Share | -0.43 X | |||
| Cash Flow From Operations | -47.84 M | |||
| Earnings Per Share | -4.33 X | |||
| Market Capitalization | 91.69 M | |||
| Total Asset | 82.81 M | |||
| Retained Earnings | -230.05 M | |||
| Working Capital | -4.74 M | |||
Performance Metrics & Calculation Methodology
ImageneBio performance is measured on a risk-adjusted basis against benchmarks. Benchmark comparison clarifies whether outcomes reflect exposure or implementation effects.
Data shown for ImageneBio is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Professional analyst research is incorporated when coverage is available. Source publication cadence can introduce delays. Return and risk statistics are calculated from historical price series.